UNSPSC 51283108: Colistimethate sodium

This classification denotes an antimicrobial solution, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XW0E5YS77G. European Medicines Agency schedules Colistimethate sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06801MIG. Colistimethate sodium generally arises in the molecular formula C57H103N16NA5O28S5.

The term COLISTIMETHATE SODIUM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 38, no. 6, 1984, list 24.) Most nations, for tariff and trade purposes, schedule colistimethate sodium under HS 29419000 and SITC 54139. Colistimethate sodium bears US NLM identifiers UMLS ID C0110462 and NCI Concept Code C65349. SMILES: As of Q4 2014, COLISTIMETHATE SODIUM remains US FDA's Preferred Term for this commodity.

UNSPSC 51283108 Colistimethate sodium is a Commodity code nominally describing a specific antimicrobial pharmaceutical agent, but the recent state and local contract opportunities tagged under it cover a broader range of medical supplies, pharmaceuticals, and pharmacy program management rather than colistimethate sodium specifically. State and local governments procuring under this code are acquiring medical and first aid supplies for emergency response, generic multi-source pharmaceuticals and OTC products through cooperative purchasing arrangements, pharmacy benefit management services, and naloxone and drug deactivation systems for community health initiatives. Issuing bodies span city purchasing departments (City of Tampa), county health authorities (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance administering programs for state and local government facilities across multiple states including Oregon).

Recent activity appears concentrated in Florida and Minnesota, with procurement also occurring in Texas. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to a county health building; the City of Tampa's Bid 26-P-00145 (posted March 25, 2026, response due March 13, 2026) for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000 and a sheltered-market set-aside for certified Small Local Business Enterprises; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, proposals due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities. The Texas Health and Human Services Commission also posted an RFI (HHS0017013, April 3, 2026) exploring direct-to-manufacturer prescription programs for self-insured health plans. The code shows no strong geographic concentration and no recent repeat buyers across multiple solicitations.